1. Generics Bulletin
  2. >>Products

Mochida And Ayumi Launch Unique Humira Biosimilar Formulation In Japan

Launch And NHI Listing Follows Approval In March This Year

 
• By Dean Rudge

A new formulation of biosimilar Humira is now available in Japan, alongside three other presentations that join biosimilar products launched by partners Viatris and Fujifilm Kyowa Kirin Biologics at the start of this year.

launch
The biosimilar was first approved in March • Source: Alamy

Partners Mochida Pharmaceutical Co., Ltd and AYUMI Pharmaceutical have secured a landmark in Japan with the launch of the first 80mg syringe for subcutaneous injection biosimilar Humira (adalimumab), alongside three other formulations.

“Adalimumab BS MA has been launched as the first adalimumab biosimilar which contains the same concentration of the active ingredient as Humira currently distributed in Japan,” the firms noted, with the launch

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Products

More from Generics Bulletin